Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial

References

• Fang T, Al Khleifat A, Meurgey J-H, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416–22.
   PubMed Web of Science ®Google Scholar
• Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208–16.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639–49.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182–94.
   PubMed Web of Science ®Google Scholar
• Younger DS, Rowland LP, Latov N, Hays AP, Lange DJ, Sherman W, et al. Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol. 1991;29:78–86.
   PubMed Web of Science ®Google Scholar
• Engel W. RNA metabolism in relation to amyotrophic lateral sclerosis. In: Rowland L, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. New York, NY: Raven Press; 1991: 125–53.
   Google Scholar
• Barbulescu M, Turner G, Seaman MI, Deinard AS, Kidd KK, Lenz J. Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr Biol. 1999;9:861–8.
   PubMed Web of Science ®Google Scholar
• Hughes JF, Coffin JM. Human endogenous retrovirus K solo-LTR formation and insertional polymorphisms: implications for human and viral evolution. Proc Natl Acad Sci. 2004;101:1668–72.
   PubMed Web of Science ®Google Scholar
• Garcia-Montojo M, Doucet-O’Hare T, Henderson L, Nath A. Human endogenous retrovirus-K (HML-2): a comprehensive review. Crit Rev Microbiol. 2018;44:715–38.
   PubMed Web of Science ®Google Scholar
• Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, et al. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 2003;63:8735–41.
   PubMed Web of Science ®Google Scholar
• Andrews WD, Tuke PW, Al-Chalabi A, Gaudin P, Ijaz S, Parton MJ, et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol. 2000;61:527–32.
   PubMed Web of Science ®Google Scholar
• Steele AJ, Al-Chalabi A, Ferrante K, Cudkowicz ME, Brown RH, Garson JA. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. 2005;64:454–8.
   PubMed Web of Science ®Google Scholar
• McCormick AL, Brown RH, Cudkowicz ME, Al-Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008;70:278–83.
   PubMed Web of Science ®Google Scholar
• MacGowan DJL, Scelsa SN, Imperato TE, Liu K-N, Baron P, Polsky B. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology. 2007;68:1944–6.
   PubMed Web of Science ®Google Scholar
• Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69:141–51.
   PubMed Web of Science ®Google Scholar
• Mayer J, Harz C, Sanchez L, Pereira GC, Maldener E, Heras SR, et al. Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins. Mol Neurodegener. 2018;13:39.
   PubMed Web of Science ®Google Scholar
• Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. 2013;99:180–7.
   PubMed Web of Science ®Google Scholar
• Garson JA, Usher L, Al-chalabi A, Huggett J, Day EF, Mccormick AL. Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2019;2:1–9.
   Google Scholar
• Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7.307ra153.
   Web of Science ®Google Scholar
• Contreras-Galindo RA, Dube D, Fujinaga K, Kaplan MH, Markovitz DM. Susceptibility of human endogenous retrovirus type-K to reverse transcriptase inhibitors. J Virol. 2017;91:e01309–17.
   PubMed Web of Science ®Google Scholar
• Tyagi R, Li W, Parades D, Bianchet MA, Nath A. Inhibition of human endogenous retrovirus-K by antiretroviral drugs. Retrovirology. 2017;14:1–13.
   PubMed Web of Science ®Google Scholar
• Westarp ME, Bartmann P, Rössler J, Geiger E, Westphal K-P, Schreiber H, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. Neuroreport. 1993;4:819–22.
   PubMed Web of Science ®Google Scholar
• Scelsa SN, MacGowan DJL, Mitsumoto H, Imperato T, LeValley AJ, Liu MH, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology. 2005;64:1298–300.
   PubMed Web of Science ®Google Scholar
• Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, et al. A revision of the El Escorial criteria – 2015. Amyotroph Lateral Sc Fr. 2015;16:291–2.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;122:S194–S5.
   Google Scholar
• Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. AJP. 2011;168:1266–77.
   Google Scholar
• Swash M, de Carvalho M. The neurophysiological index in ALS. Amyotroph Lateral Sc. 2004;5:108–10.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, Schultz DW, Benatar M, Rogers ML. Urinary p75 (ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137–1143.
   PubMed Web of Science ®Google Scholar
• Lu C-H, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86:565–73.
   PubMed Web of Science ®Google Scholar
• Laderoute MP, Giulivi A, Larocque L, Bellfoy D, Hou Y, Wu H-X, et al. The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia. Aids. 2007;21:2417–24.
   PubMed Web of Science ®Google Scholar
• Laderoute MP, Larocque LJ, Giulivi A, Diaz-Mitoma F. Further evidence that human endogenous retrovirus K102 is a replication competent foamy virus that may antagonize HIV-1 replication. TOAIDJ. 2015;9:112–22.
   Google Scholar
• Dube D, Contreras-Galindo R, He S, King SR, Gonzalez-Hernandez MJ, Gitlin SD, et al. Genomic flexibility of human endogenous retrovirus type K. J Virol. 2014;88:9673–82.
   PubMed Web of Science ®Google Scholar
• Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Sc Fr. 2014;15:279–84.
   PubMed Web of Science ®Google Scholar
• Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1–48.
   Web of Science ®Google Scholar
• Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med. 2018;24:379–94.
   PubMed Web of Science ®Google Scholar
• Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system? J Med Life. 2011;4:432–9.
   PubMedGoogle Scholar
• Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014;59:1032–7.
   PubMed Web of Science ®Google Scholar
• De Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456–60.
   PubMed Web of Science ®Google Scholar
• Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids. 2005;19:399–406.
   PubMed Web of Science ®Google Scholar
• Lu C-H, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–57.
   PubMed Web of Science ®Google Scholar
• Park SB, Vucic S, Cheah BC, Lin CS, Kirby A, Mann KP, et al. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine 2015;2:1916–22.
   PubMed Web of Science ®Google Scholar